Many clinical trials rely on patient-reported outcomes to determine whether drugs are working, but with disparate methods employed across the industry, it can be difficult to compare the results from one study with those of another. With that in mind, the FDA has recruited CRO giant Icon to help develop an industry standard for patient polling in antibacterial R&D.
PPD has expanded its relationship with eClinical outfit Medidata, combining technologies in risk-based monitoring to help sponsors use real-time safety data to make decisions on clinical trials.
Contract drug developer AMRI watched its shares plummet after underperforming in the third quarter, an earnings miss the company blamed on declining demand, spiking costs and bad weather in the desert.
Chinese CRO WuXi PharmaTech has opened up shop in Israel, cutting the ribbon on a Tel Aviv outpost and aligning itself with a local investor to expand its presence in the country.
CRO conglomerate PRA is angling to be the next contract drug developer to make a splash on Wall Street, setting terms for a $400 million IPO.
Baltimore CRO Paragon Bioservices has raised a $13 million A round, money it'll spend to stretch out its offerings in biologics R&D and manufacturing.
Diagnostics giant LabCorp is buying its way into the upper ranks of the CRO business, signing a deal to pay $5.6 billion for Covance and create an end-to-end testing conglomerate.
A string of acquisitions has revenue rolling at Charles River Laboratories, and the CRO has inked another M&A deal it hopes will pay off with a larger market share.
Quintiles, the world's largest CRO, is rolling toward its biggest year yet on the heels of a fourth straight quarter with more than $1 billion in sales.
SRI International's in-house CRO has opened up a new Phase I center, expanding its footprint in the market for early-stage research.
CRO inVentiv Health is dumping out its own trial document storage system and replacing it with Veeva Systems' cloud-based platform, a move the eClinical provider touts as a major affirmation of its technology.
MPI Research has acquired fellow Michigan CRO Jasper Clinical Research and Development for an undisclosed sum, a move that will augment the company's offerings in Phase I trials.
The Association of Clinical Research Organizations, which represents the world's largest CROs, is putting together a sort of contractors' council to weigh in on the efforts of TransCelerate BioPharma, a nonprofit group run by the biggest names in drug development.
WuXi PharmaTech has struck a deal with the genomics experts at Foundation Medicine, signing on to offer the company's cancer-decoding services to drug developers in its native China.
CRO giant Icon charted double-digit revenue growth in the third quarter, chugging toward its best-ever year and lifting its earnings projections in the process.
The world's largest CROs are reaping the benefits of two major market trends: Big Pharma is finally getting back to spending big on R&D after some lean years post-downturn, and biotech is enjoying a protracted bit of bullishness that has lined pockets around the industry.
Charles River Laboratories has unveiled a new technology it says can better test for impurities by combining two common methods into a single product, making for a flexible solution.
Observed glitches with Thermo Fisher's popular drug development software have led to concerns that data used to win approvals may have been faulty, and the company is working alongside regulators to figure out just how widespread the issue may be.
DKSH, a well-heeled pharma marketing operation, has reupped with Roche, expanding a long-standing agreement to include more of Asia.
PPD has signed a master service agreement with Swiss biotech Sellas, lending its drug development expertise to the company's efforts to advance a portfolio of treatments.